ArticleFrontiers in medicine2026
Effect of curcumin combined with vedolizumab on disease activity in patients with moderate to severe ulcerative colitis and its correlation with inflammatory and immune factors.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the clinical efficacy and immunomodulatory effects of curcumin (Cur) combined with vedolizumab (VDZ) in patients with moderate-to-severe ulcerative colitis (UC). Methods: A prospective, multicenter, randomized controlled double-blind study was conducted. Patients with moderate-to-severe UC admitted between March 2021 and March 2024 were enrolled and randomly assigned to either the VDZ monotherapy group (76 cases) or the VDZ combined with Cur combination group (83 cases). The treatment period was 26 weeks. The primary outcome was the clinical remission rate at 26 weeks. Secondary outcomes included the remission rate at 14 weeks, the disease activity index (DAI), inflammatory and immune markers, and safety. Results: The combination group showed significantly higher clinical remission rates at both 26 and 14 weeks compared to the VDZ group ( Conclusion: Curcumin as an combination group to VDZ significantly improves clinical remission rates, alleviates inflammatory and immune imbalances in patients with moderate-to-severe UC, without increasing safety risks, highlighting its important clinical translational value. This study provides new evidence for combination treatment strategies in UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.